Transforming growth factor beta type I receptor kinase (TGF-βRI)

Transforming growth factor beta type I receptor kinase (TGF‑βRI, also known as ALK5) is a single-pass transmembrane serine/threonine protein kinase that serves as a key signal-transducing component of the transforming growth factor beta (TGF‑β) superfamily pathway. Upon ligand binding to its partner receptor (TGF‑βRII), TGF‑βRI is phosphorylated by TGF‑βRII, which activates its cytoplasmic serine/threonine kinase domain. This activation leads to phosphorylation of downstream effectors such as SMAD proteins or other non-SMAD targets including PI3K/AKT and RhoA pathways. Through these mechanisms, TGF‑βRI regulates diverse biological processes including cell proliferation, differentiation, apoptosis, immune responses, wound healing/tissue repair, extracellular matrix production/fibrosis formation—and plays critical roles both physiologically and pathologically. Dysregulation or aberrant activation/inhibition of TGF‑βRI has been implicated in cancer progression/metastasis (by modulating tumor microenvironment), fibrotic diseases (by promoting excessive extracellular matrix deposition), chronic inflammation/autoimmunity (via immune suppression), among others. The central role it plays makes it an important therapeutic target; several small-molecule inhibitors have been developed to block its activity for potential treatment of cancer and fibrotic conditions.

Other names

TGF-β type I receptorActivin receptor-like kinase 5 (ALK5)TGFBR1ALK5 kinaseTGFβRI

Inhibition of serine/threonine kinase activity to block downstream SMAD-dependent or SMAD-independent signaling pathways involved in cell proliferation, migration, immune modulation, and fibrosis.